Left ventricular ejection fraction

There are 768 papers on left ventricular ejection fraction in aging research: 102 trials and 523 observational studies in people, 42 in animals, 69 reviews.

Biomarker

768 papers study it336 more mention it130 findings

316 new papers in 30 daysSee all 1,104 papers on left ventricular ejection fraction

“A ≥1 SD increase in PWV was associated with a mean LVEF decline of 2.7% (95% CI -4.65 to -0.81, p=0.006).”
Atorvastatin and Pulse Wave Velocity in Anthracycline-based ChemotherapyAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4357286
  • Human trial102
  • Humans523
  • Animals42
  • In silico9

Interventions

41

SGLT2 inhibitors

upin humans7no changein humans1+0.6% per year

8 studies
  1. SGLT2 inhibitors increase left ventricular ejection fraction in humans (on top of GDMT versus placebo) (MD +3.59%; 95% CI 1.12–6.06; p=0.004).

    “and increase in LVEF (MD +3.59%; 95% CI 1.12–6.06; p=0.004)”

    Human trialon top of GDMT versus placebo

    SGLT-2 inhibitors in moderate-to-severe functional mitral regurgitation: a meta-analysis of randomized controlled trials

    ESC Congress 2026 abstract

  2. SGLT2 inhibitors increase left ventricular ejection fraction in humans (post-ACS diabetic patients, SGLT2i group vs control, at 3 months) (49.9% to 51.9%).

    “with significant increases in LVEF (49.9% to 51.9%, p<0.001)”

    Human trialpost-ACS diabetic patients, SGLT2i group vs control, at 3 monthsleft ventricle3 monthsn = 25

    Effect of SGLT2 inhibitors on left atrial strain in patients of acute coronary syndrome and diabetes mellitus

    ESC Congress 2026 abstract

  3. SGLT2 inhibitors increase left ventricular ejection fraction in patients with diabetes mellitus, hypertension and coronary artery disease.

    “The left ventricular ejection fractions, quality of life scores and overall clinical response rates were higher (P<0.05).”

    Human trialin patients with diabetes mellitus, hypertension and coronary artery diseaseheart

    Role of sodium glucose cotransporter-2 (SGLT2) inhibitors in the modulation of QTc interval and ventricular arrhythmia in patients with diabetes mellitus combined with hypertension and coronary artery disease

    Pakistan journal of pharmaceutical sciences

  4. SGLT2 inhibitors increase left ventricular ejection fraction in patients with type 2 diabetes mellitus and coronary artery disease (+ 4.6% vs − 1.0%, p ≤ 0.01).

    “increased LV ejection fraction (+ 4.6% vs − 1.0%) (all p ≤ 0.01)”

    Human trialin patients with type 2 diabetes mellitus and coronary artery disease6 monthsn = 302

    Cardiometabolic Impact of SGLT-2 Inhibitors on Epicardial Adiposity and Left Ventricular Function in Type 2 Diabetes Mellitus and Coronary Artery Disease: Insights from Malaysian Epicad Study

    Research SquarePreprint

  5. SGLT2 inhibitors were not clearly linked with left ventricular ejection fraction in humans (type 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison).

    “LVEF remained stable”

    Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparisonheartempagliflozin 10 mg/day or dapagliflozin 10 mg/day6 monthsn = 51

    Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study

    Research SquarePreprint

  6. SGLT2 inhibitors are linked with better left ventricular ejection fraction in patients with type 2 diabetes and cancer receiving antineoplastic therapy.

    “Echocardiography showed improved left ventricular ejection fraction (LVEF) and reduced left ventricular end-diastolic diameter (LVID)/left atrial (LA) dimensions (all p < .001).”

    Humansin patients with type 2 diabetes and cancer receiving antineoplastic therapyleft ventricle

    SGLT2 inhibitors mitigate cardiorenal toxicity and improve survival in type 2 diabetes mellitus patients undergoing antineoplastic therapy: A multicenter retrospective cohort study

    International journal of cancer

  7. SGLT2 inhibitors are linked with better left ventricular ejection fraction in patients with Fabry disease on Fabry-specific therapy (+0.6% per year).

    “a slight but significant improvement of LVEF by 0.6% per year (p = 0.0319) was observed, which was more prominent in males with a reduced LVEF (< 50%) at baseline”

    Humansin patients with Fabry disease on Fabry-specific therapyheart12 monthsn = 48

    Impact of SGLT2 inhibitors in patients with Fabry disease

    Clinical research in cardiology : official journal of the German Cardiac Society

  8. SGLT2 inhibitors increase left ventricular ejection fraction in humans (heart failure; compared with placebo) (MD +1.90; 95% CI 0.63 to 3.17).

    “SGLT2 inhibitors significantly improved LVEF (MD +1.90; 95% CI 0.63 to 3.17; P = 0.003)”

    Reviewheart failure; compared with placeboheartn = 868

    Reverse Remodeling with SGLT2 Inhibition on Cardiac MRI in Heart Failure A Meta Analysis of Randomized Trials

    AHA Scientific Sessions 2026 abstract

More on SGLT2 inhibitors

Dapagliflozin

upin humans6upin mice1

7 studies
  1. Dapagliflozin increases left ventricular ejection fraction in humans (patients with sepsis receiving standardized treatment) (Median 60.0% versus 55.0% in controls).

    “On the 5th day of treatment, the median LVEF was significantly higher in the intervention group”

    Human trialpatients with sepsis receiving standardized treatmentheart10 mg5 days

    A preliminary study on the protective effect of dapagliflozin on multi-organ function in the early stage of sepsis

    Zhonghua nei ke za zhi

  2. Dapagliflozin increases left ventricular ejection fraction in humans (non-diabetic patients with AMI after PCI) (52.24% vs 47.66%).

    “Group I demonstrated superior cardiac improvement: higher LVEF (52.24 % vs. 47.66 %; p = 0.025)”

    Human trialnon-diabetic patients with AMI after PCIleft ventricle6 months

    Early Dapagliflozin in Non-diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling (EARLY DAPA-AMI)

    Journal of the Saudi Heart Association

  3. Dapagliflozin improves left ventricular ejection fraction in patients with HFrEF combined with T2DM.

    “After treatment, the pancreatic beta-cell function index, left ventricular ejection fraction, and glomerular filtration rate of patients in the study group were significantly higher than control group (P < 0.001)”

    Human trialin patients with HFrEF combined with T2DM

    Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

    World journal of diabetes

  4. Dapagliflozin is linked with better left ventricular ejection fraction in HFrEF and HFpEF patients (+3.2% in HFrEF, +0.9% in HFpEF).

    “LVEF increased in HFrEF (+3.2%) and HFpEF (+0.9%).”

    Humansin HFrEF and HFpEF patients3 months

    Dapagliflozin and ventricular repolarization across heart failure phenotypes

    Current medical research and opinion

  5. Dapagliflozin is linked with higher left ventricular ejection fraction in humans (+5.98 ± 7.39% points).

    “mean LVEF increased from baseline to follow-up by 5.98 ± 7.39% points among 213 patients with paired LVEF data (paired p < 0.001)”

    Humansn = 213

    Real-world utilization, safety, and observed clinical outcomes of dapagliflozin among Sudanese patients with heart failure: a multicenter retrospective cohort study

    Scientific reports

  6. Dapagliflozin is linked with higher left ventricular ejection fraction in humans (2DE: 36.6±8.8 vs. 34.5±7.7%; 3DE: 37.4±8.7 vs. 34.4±7.9%; p < 0.001).

    “After 6MFU, left ventricular (LV) end-diastolic and end-systolic volumes reduced, and LVEF increased”

    HumansHeart failure with reduced ejection fraction on guideline-directed therapy; before-and-after comparisonheart10 mg daily6 monthsn = 75

    DAPAgliflozin-Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA-REM Study

    Echocardiography (Mount Kisco, N.Y.)

  7. Dapagliflozin improves left ventricular ejection fraction in mice (experimental myocardial infarction).

    “Consistently, echocardiography showed improved left ventricular ejection fraction and reduced ventricular dilation after MI.”

    Animalsexperimental myocardial infarctionheart

    Dapagliflozin attenuates post-infarction inflammation and remodeling via promoting metabolic reprogramming–driven cardiac lymphangiogenesis

    ESC Congress 2026 abstract

More on Dapagliflozin

Exercise

upin humans2no changein humans1upin mice1

4 studies
  1. Exercise improves left ventricular ejection fraction in humans (chronic heart failure).

    “LVEF in the rehabilitation group was higher than that in the control group, and LVESV and LVEDV were both lower than those in the control group (P<0.05)”

    Human trialchronic heart failure3 monthsn = 92

    Effect of Exercise Rehabilitation Therapy on Cardiopulmonary Function, Cardiac Pumping Function, NT-proBNP, and Quality of Life in Elderly Patients with Chronic Heart Failure

    Chinese Health Care

  2. Exercise improves left ventricular ejection fraction in humans (chronic heart failure).

    “The experimental group demonstrated significant improvements in the 6-minute walk test, left ventricular ejection fraction, and quality of life compared to the control group (P < 0.05).”

    Human trialchronic heart failure12 weeksn = 80

    Impact of Resilience-Based Exercise on Quality of Life and Cardiac Function in Elderly CHF Patients

    GSA 2025 abstract

  3. Exercise increases left ventricular ejection fraction in doxorubicin-treated mice.

    “Echocardiography revealed restored systolic function with elevated left ventricular ejection fraction (LVEF) and fractional shortening (LVFS).”

    Animalsin doxorubicin-treated miceheartmales

    Involvement of TRPC6/NFAT Axis and Mitochondrial Quality Control in the Protective Effect of Aerobic Exercise against Doxorubicin-Induced Cardiomyopathy

    Research SquarePreprint

  4. Exercise showed no clear effect on left ventricular ejection fraction in atrial fibrillation patients.

    “it does not significantly improve ejection fraction or heart rate”

    Reviewin atrial fibrillation patientsn = 1,251

    Cardiopulmonary fitness and quality of life improvements in atrial fibrillation patients following exercise-based cardiac rehabilitation: meta-analysis of randomized control trials

    Clinics (Sao Paulo, Brazil)

More on Exercise

Empagliflozin

no changein humans1upin pigs1

2 studies
  1. Empagliflozin showed no clear effect on left ventricular ejection fraction in humans (older adults with overweight and at least one heart failure risk factor).

    “No significant differences were observed for LV volumes or ejection fraction.”

    Human trialolder adults with overweight and at least one heart failure risk factorleft ventricle10 mg daily180 daysn = 165

    The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial

    Journal of cardiac failure

  2. Empagliflozin increases left ventricular ejection fraction in pigs (pacemaker-induced premature ventricular contractions) (50 ± 10.2% with empagliflozin versus 34 ± 4.35% in the PVC group).

    “whereas EMPA attenuated LV dysfunction (50 ± 10.2, p=0.059)”

    Animalspacemaker-induced premature ventricular contractionsleft ventricle0.5 mg/kg/day12 weeks

    Empagliflozin Prevents Left Ventricular Dysfunction and Cardiac Remodeling Induced by a High Burden of Premature Ventricular Contractions in Swine

    AHA Scientific Sessions 2026 abstract

More on Empagliflozin

Essential amino acids

upin humans1

1 study
  1. Essential amino acids improve left ventricular ejection fraction in humans (from 34.3 ± 1.5 to 35.80 ± 1.7%).

    “Of particular interest, after six months’ follow-up, there was a significant improvement in LVEF (from 34.3 ± 1.5 to 35.80 ± 1.7%, p < 0.001) and GLS (−8.5 ± 1.07 vs. −11.9 ± 1.23, p < 0.001).”

    Human trial6 monthsn = 60

    Early Effect of Supplementation with Essential Amino Acids on Cardiac Performance in Elderly Patients with Heart Failure and Sarcopenia

    International journal of molecular sciences

  2. Essential amino acids improve left ventricular ejection fraction in humans (chronic heart failure with reduced ejection fraction and sarcopenia).

    “after 6 months' follow-up, there was a significant improvement in LVEF and global longitudinal strain (GLS).”

    Human trialchronic heart failure with reduced ejection fraction and sarcopenia6 monthsn = 60

    Early Effect of Supplementation with Essential Amino Acids on Cardiac Performance in Elderly Patients with Heart Failure and Sarcopenia

    International journal of molecular sciences

More on Essential amino acids

Exercise rehabilitation based on medical care-family integration

upin humans1

1 study
  1. Exercise rehabilitation based on medical care-family integration increases left ventricular ejection fraction in humans.

    “After intervention, the 6 MWD and LVEF were higher, while the NT-proBNP level and LVEDD were significantly lower in the exercise rehabilitation group compared to the conventional rehabilitation group (P < 0.05).”

    Human trial3 monthsn = 118

    Exercise rehabilitation based on medical care-family integration in older patients with chronic heart failure and psychological problems

    World journal of psychiatry

  2. Exercise rehabilitation based on medical care-family integration increases left ventricular ejection fraction in older patients with chronic heart failure and psychological problems (P < 0.05).

    “LVEF values were higher compared to the conventional rehabilitation group (P < 0.05).”

    Human trialin older patients with chronic heart failure and psychological problemsn = 118

    Exercise rehabilitation based on medical care-family integration in older patients with chronic heart failure and psychological problems

    World journal of psychiatry

More on Exercise rehabilitation based on medical care-family integration

Home-based cardiac telerehabilitation

upin humans1

1 study
  1. Home-based cardiac telerehabilitation increases left ventricular ejection fraction in humans (at 6 months) (7.7% versus 3.8%).

    “There was a significant improvement in the cardiac function in intervention group compared with control group after 6 months.”

    Human trialat 6 months6-month periodn = 81

    Effectiveness of home-based telerehabilitation programs on functional capacity and cardiac function in elderly heart failure patients: A prospective longitudinal study

    Medicine

  2. Home-based cardiac telerehabilitation increases left ventricular ejection fraction in humans (heart failure with left ventricular ejection fraction <40%) (+7.7% absolute, +25.6% relative, P < .05, 95% CI -7.8 to -0.5).

    “Left ventricular ejection fraction increased by 7.7%, which corresponds to 25.6% in relative terms (P < .05, 95% confidence interval -7.8 to -0.5).”

    Human trialheart failure with left ventricular ejection fraction <40%6-monthn = 40

    Effectiveness of home-based telerehabilitation programs on functional capacity and cardiac function in elderly heart failure patients: A prospective longitudinal study

    Medicine

More on Home-based cardiac telerehabilitation

Multidisciplinary cardiac case conference

upin humans1

1 study
  1. Multidisciplinary cardiac case conference is linked with higher left ventricular ejection fraction in humans (heart failure with reduced ejection fraction) (+12.1±10.8%).

    “Mean LVEF improved +12.1±10.8% (p<0.001)”

    Humansheart failure with reduced ejection fractionleft ventriclen = 89

    Multidisciplinary cardiac case conference overcomes therapeutic inertia in heart failure: achieving guideline-directed therapy in high-risk populations

    ESC Congress 2026 abstract

More on Multidisciplinary cardiac case conference

Sleeve gastrectomy

upin humans1

1 study
  1. Sleeve gastrectomy increases left ventricular ejection fraction in humans (patients with obesity; compared with control) (MD 16.50%; 95% CI 10.41–22.59).

    “SG significantly increased LVEF (MD 16.50%; 95% CI 10.41–22.59) and reduced LV end-diastolic diameter (MD −5.20 mm; 95% CI −8.67 to −1.73).”

    Reviewpatients with obesity; compared with controlheart1 year

    Effects of glucagon-like peptide 1 receptor agonists versus bariatric surgeries on cardiac function improvement: a network meta-analysis

    ESC Congress 2026 abstract

More on Sleeve gastrectomy

Cardio-oncology disease management program

upin humans1

1 study
  1. Cardio-oncology disease management program increases left ventricular ejection fraction in humans (Change 4.26±5.66% versus 1.13±6.94%; p=0.001).

    “CO-DMP was associated with significant between group differences in myocardial function, including greater improvements in LVEF (4.26±5.66% vs 1.13±6.94%; p=0.001)”

    Human triallong-term cancer survivors with subclinical/Stage B heart failure; compared with usual careheart6 monthsn = 144

    Risk-guided disease management to prevent heart failure in adult cancer survivors of previous cardiotoxic cancer treatments (REDEEM) trial

    ESC Congress 2026 abstract

More on Cardio-oncology disease management program

Luseogliflozin

upin humans1

1 study
  1. Luseogliflozin improves left ventricular ejection fraction in humans (type 2 diabetes, per-protocol analysis) (72.7 ± 4.9 vs 75.7 ± 4.6, p = 0.033; interaction p = 0.041).

    “Luseogliflozin significantly improved LVEF (72.7 ± 4.9 vs 75.7 ± 4.6 p = 0.033”

    Human trialtype 2 diabetes, per-protocol analysisheartweek 24n = 33

    Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

    ADA Scientific Sessions 2026 abstract

More on Luseogliflozin

Psychological support

upin humans1

1 study
  1. Psychological support improves left ventricular ejection fraction in patients with chronic heart disease (56.2 ± 6.1% vs. 54.1 ± 6.3%).

    “Cardiac imaging also improved, with higher left ventricular ejection fraction (56.2 ± 6.1% vs. 54.1 ± 6.3%)”

    Human trialin patients with chronic heart disease12 monthsn = 200

    The impact of psychological support strategies on clinical outcomes and quality of life in patients with chronic heart disease: a randomized controlled trial

    Journal of cardiothoracic surgery

More on Psychological support

Glycemic optimization

upin humans1

1 study
  1. Glycemic optimization increases left ventricular ejection fraction in humans (newly diagnosed type 2 diabetes) (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01).

    “CMR evaluation revealed increases in left ventricle (LV) ejection fraction (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01)”

    Human trialnewly diagnosed type 2 diabetes12 monthsn = 20

    Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study

    Cardiovascular diabetology

More on Glycemic optimization

Augmented reality-based sensory interaction device

upin humans1

1 study
  1. Augmented reality-based sensory interaction device improves left ventricular ejection fraction in humans (chronic heart failure) (54.11% vs. 51.85%).

    “Post-intervention analysis revealed significant improvements in the intervention group across several parameters, including left ventricular ejection fraction (LVEF: 54.11% vs. 51.85%, P < 0.001)”

    Human trialchronic heart failurefour-weekn = 200

    Research on the effect of augmented reality based sensory interaction device in rehabilitation training of patients with chronic heart failure

    BMC cardiovascular disorders

More on Augmented reality-based sensory interaction device

Running

downin humans1

1 study
  1. Running decreases left ventricular ejection fraction in humans (immediately post-race).

    “Immediately post-race, LVEF decreased slightly but remained within the normal range”

    Human trialimmediately post-racen = 105

    Exercise-induced ventricular changes in recreational half-marathon runners compared with marathon/ultramarathon runners

    International journal of cardiology. Heart & vasculature

More on Running

All 41

Effects

6

Physical function

no changein humans1

1 study
  1. Left ventricular ejection fraction was not clearly linked with physical function in patients with cardiovascular disease.

    “Left ventricular ejection fraction had no significant association with functional outcomes.”

    Humansin patients with cardiovascular diseasen = 61

    Characteristics of Cardiorespiratory Fitness and Physical Performance According to Sarcopenia-related Phenotypes in Patients with Cardiovascular Disease: A Case Series

    KOREAN ACADEMY OF CARDIORESPIRATORY PHYSICAL THERAPY

Sarcopenia

no changein silico1

1 study
  1. Left ventricular ejection fraction showed no clear effect on sarcopenia in silico.

    “there was no evidence of a causal effect of LVEF on any of the 3 sarcopenia-related traits.”

    In silico

    Sarcopenia-related traits and left ventricular ejection fraction: A bidirectional Mendelian randomization study

    Interdisciplinary Nursing Research

More on Sarcopenia

Kansas City Cardiomyopathy Questionnaire-12

no changein humans1

1 study
  1. Left ventricular ejection fraction was not clearly linked with Kansas City Cardiomyopathy Questionnaire-12 in humans (chronic heart failure).

    “Left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide showed no significant association with health status.”

    Humanschronic heart failuren = 150

    Independent contributions of functional class, comorbidity, and frailty to health status in elderly adults with heart failure

    medRxivPreprint

More on Kansas City Cardiomyopathy Questionnaire-12

NfL

no changein humans1

1 study
  1. Left ventricular ejection fraction was not clearly linked with NfL in humans.

    “nor were echocardiographic variables associated with NfL or GFAP”

    Humansn = 962

    Subclinical cardiac dysfunction and circulating markers of brain injury in older adults: The cardiovascular health study

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

More on NfL

Kansas City Cardiomyopathy Questionnaire

no changein humans1

1 study
  1. Left ventricular ejection fraction was not clearly linked with Kansas City Cardiomyopathy Questionnaire in humans (transthyretin cardiac amyloidosis).

    “Gender, ATTR-CA type, phenotype, and LVEF were not associated with health status.”

    Humanstransthyretin cardiac amyloidosisn = 138

    Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study

    Aging clinical and experimental research

More on Kansas City Cardiomyopathy Questionnaire

Number of hospital readmissions

downin humans1

1 study
  1. Left ventricular ejection fraction is linked with lower number of hospital readmissions in humans (acute heart failure) (standardized regression coefficient -0.32).

    “LVEF (-0.32), and degree of frailty (0.29) were extracted as significant factors.”

    Humansacute heart failure

    Frailty in elderly patients with acute heart failure increases readmission

    Heart & lung : the journal of critical care

Upstream

9

Hypertensive disorders of pregnancy

no changein humans1

1 study
  1. Hypertensive disorders of pregnancy was not clearly linked with left ventricular ejection fraction in humans After adjustment for cardiovascular risk factors (β = 0.76, 95% CI -0.38 to 1.90).

    “left ventricular ejection fraction (β = 0.76, 95% CI -0.38 to 1.90, p = 0.193)”

    HumansAfter adjustment for cardiovascular risk factorsheartfemales

    Long-term multisystem organ damage following hypertensive disorders of pregnancy across clinical risk subgroups: a UK Biobank study

    Frontiers in cardiovascular medicine

More on Hypertensive disorders of pregnancy

Preeclampsia

no changein humans1

1 study
  1. Preeclampsia showed no clear effect on left ventricular ejection fraction in humans (Preeclampsia compared with controls).

    “Left ventricular ejection fraction and right ventricular function remained similar in the preeclampsia and control groups throughout.”

    ReviewPreeclampsia compared with controlsheartfemales

    Cardiac Structure and Function in Women After Preeclampsia: A Systematic Review and Meta-Analysis

    JACC. Heart failure

More on Preeclampsia

Lipoprotein

downin humans1

1 study
  1. Lipoprotein is linked with lower left ventricular ejection fraction in Hispanic subjects (β, -0.75 [95% CI, -1.34 to -0.17]).

    “Each 1-SD increase in log-transformed Lp(a) was associated with an increase in left ventricular end-systolic volume index (β, 0.60 [95% CI, 0.02-1.18]), and left atrial minimum volume index (β, 0.81 [95% CI, 0.09-1.52]), and a decline in left ventricular ejection fraction (β, -0.75 [95% CI, -1.34 to -0.17]), and total left atrial emptying fraction (β, -1.17 [95% CI, -2.09 to -0.24]) in Hispanic subjects over a decade.”

    Humansin Hispanic subjects10 yearsn = 2,366

    Association Between Lipoprotein(a) and Cardiac Remodeling Across Race and Ethnicity in the Multi-Ethnic Study of Atherosclerosis

    Circulation. Population health and outcomes

More on Lipoprotein

Automated deep learning analysis of echocardiography

upin humans1

1 study
  1. automated deep learning analysis of echocardiography is linked with higher left ventricular ejection fraction in humans (hospitalized patients) (mean difference 5.8%, P < 0.001).

    “AI-derived LVEF values were significantly higher than human estimates (mean difference 5.8%, P < 0.001).”

    Humanshospitalized patientsn = 731

    Association of echocardiographic findings with mortality: human assessment vs. automated deep learning analysis

    European heart journal. Digital health

Age

no changein humans1

1 study
  1. Age was not clearly linked with left ventricular ejection fraction in humans (healthy).

    “LVEF was similar across age groups.”

    Humanshealthyheart

    What is a normal left ventricular ejection fraction in healthy adults? A meta-analysis of population-based echocardiographic studies

    Journal of cardiovascular imaging

Sarcopenia

downin humans1

1 study
  1. Sarcopenia is linked with lower left ventricular ejection fraction in elderly patients with coronary heart disease (p < 0.05).

    “The sarcopenia group showed lower cardiac output and left ventricular ejection fraction levels than the non-sarcopenia group”

    Humansin elderly patients with coronary heart diseasen = 318

    Occurrence of sarcopenia in elderly patients with coronary heart disease and its association with short-term prognosis

    BMC cardiovascular disorders

More on Sarcopenia

Female sex

upin humans1

1 study
  1. Female sex is linked with higher left ventricular ejection fraction in humans (older BASE-II subsample).

    “Echocardiography revealed that left ventricular ejection fraction was higher in women than in men”

    Humansolder BASE-II subsamplen = 1,100

    Cohort profile: follow-up of a Berlin Aging Study II (BASE-II) subsample as part of the GendAge study

    BMJ open

Atrial fibrillation

downin humans1

1 study
  1. Atrial fibrillation is linked with lower left ventricular ejection fraction in hypertensive patients (p < 0.05).

    “Left Ventricular Ejection Fraction (LVEF) were significantly decreased”

    Humansin hypertensive patientsn = 155

    The Impact of Hypertension and Atrial Fibrillation on Cognitive Decline and Subclinical Atherosclerosis

    Brain sciences

More on Atrial fibrillation

Progeria

upin humans1

1 study
  1. Progeria is linked with higher left ventricular ejection fraction in humans (compared to older healthy volunteers).

    “Children with HGPS had higher left ventricular ejection fraction (LVEF) and global longitudinal strain, when compared to older healthy volunteers (P < 0.05)”

    Humanscompared to older healthy volunteersleft ventriclen = 7

    Ultrasonic Characteristics of Cardiovascular Changes in Children with Hutchinson-Gilford Progeria Syndrome: A Comparative Study with Normal Children and Aging People

    BioMed research international

More on Progeria

Associations

44

Mortality

upin humans4downin humans4HR 0.66–2.28

8 studies
  1. Left ventricular ejection fraction predicts mortality in humans (Heart failure; reduced LVEF; multivariable model) (HR 1.33, 95% CI 1.27–1.38).

    “reduced LVEF (HR 1.33, 95% CI 1.27–1.38)”

    HumansHeart failure; reduced LVEF; multivariable model202453.6% womensn = 149,703

    Total illness burden strongly predicts heart failure death

    ESC Congress 2026 abstract

  2. Left ventricular ejection fraction is associated with mortality in humans (non-obstructive coronary artery disease) (HR 0.978; 95% CI: 0.968–0.989).

    “LVEF (HR 0.978; 95% CI: 0.968–0.989), and LVMI (HR 1.008; 95% CI: 1.003–1.012) were associated with mortality.”

    Humansnon-obstructive coronary artery diseasemales

    Cardiovascular-renal-metabolic syndrome and mortality in non-obstructive coronary artery disease: prognostic impact of diabetes in women

    ESC Congress 2026 abstract

  3. Left ventricular ejection fraction predicts mortality in humans (multivariable analysis in STEMI patients after primary PCI) (OR 2.71, p=0.029).

    “post-PCI LVEF <40% (OR 2.71; p=0.029)”

    Humansmultivariable analysis in STEMI patients after primary PCIn = 585

    Safely expanding early discharge in STEMI: clinical and artificial intelligence tools for low-risk identification

    ESC Congress 2026 abstract

  4. Left ventricular ejection fraction predicts mortality in humans (acute heart failure) (HR 1.16, P<0.001).

    “All 3 indices predicted mortality (per 10% decrease in LVEF: hazard ratio (HR) 1.16”

    Humansacute heart failuremedian follow-up of 32.6 monthsn = 3,688

    Misperception in Heart Failure Phenotyping: Moving Beyond the Chamber to the Myocardium

    Journal of the American Heart Association

  5. Left ventricular ejection fraction predicts mortality in humans (LVEF <50%: HR 2.28, 95% CI 1.78–2.93; P ≤ .0001).

    “left ventricular ejection fraction (LVEF) <50% (2.28 [1.78-2.93], P ≤ .0001)”

    HumansLeft ventricular ejection fraction <50%; after minimally invasive mitral valve repair; multivariable modeln = 501

    Obesity Does Not Influence the Outcomes of Minimally Invasive Mitral Valve Repair for Mitral Regurgitation: A Longitudinal Analysis

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

  6. Left ventricular ejection fraction is linked with a lower risk of mortality in humans (HR 0.66, P < 0.001).

    “(5% increase of left ventricular ejection fraction: HR 0.66; P < 0.001) were significantly associated with outcome.”

    Humans5% increase6 monthsn = 69

    Short- and long-term survival in patients over 90 years old undergoing pacemaker implantation

    Journal of cardiovascular medicine (Hagerstown, Md.)

  7. Left ventricular ejection fraction is associated with mortality in octogenarian population.

    “left ventricular ejection fraction (P=0.003), serum albumin (P=0.020), C-Reactive protein (P=0.020) and renin-angiotensin system inhibitors at hospital discharge were negatively correlated with mortality”

    Humansin octogenarian populationheart1-year follow-upn = 170

    Characteristics and outcomes of octogenarians with revascularized critical limb ischemia: Impact of altered cardiac function for early mortality

    Journal de medecine vasculaire

  8. Left ventricular ejection fraction predicts mortality in humans (Ambulatory patients with heart failure) (OR 0.93, CI 0.86–0.99; p = 0.05).

    “left ventricular ejection fraction (OR 0.93, CI 0.86-0.99, p = 0.05), and peak VO2 (OR 0.78, CI 0.65-0.94, p = 0.008) were predictors of death.”

    HumansAmbulatory patients with heart failureheartMean follow-up of 21 monthsn = 130

    Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure

    Wiener klinische Wochenschrift

SGLT2 inhibitors

upin humans2+51% patients showed improvement

2 studies
  1. SGLT2 inhibitors are associated with left ventricular ejection fraction in humans (heart failure; uncontrolled comparison with baseline) (Median LVEF 28.8% at baseline versus 31.6% at 6 months; paired LVEDV and LVESV changes −13.0% and −16.3%).

    “SGLT2i initiation was followed by modest LV volume reduction and a small LVEF increase.”

    Humansheart failure; uncontrolled comparison with baselineleft ventricle6 monthsn = 101

    Changes in Left Ventricular Volumes and Function After Initiation of Sodium–Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Predominantly Reduced Ejection Fraction: A Real-World Echocardiographic Study

    Journal of clinical medicine

  2. SGLT2 inhibitors are associated with left ventricular ejection fraction in humans (51.4% of patients showed improvement).

    “More than half (51.4%) showed LVEF improvement”

    Humansheart

    Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure

    Frontiers in cardiovascular medicine

More on SGLT2 inhibitors

Female sex

upin humans2

2 studies
  1. Female sex is associated with left ventricular ejection fraction in humans (healthy) (63.7% vs 61.9%).

    “Women had higher mean LVEF (63.7%) than men (61.9%), with corresponding lower normal limits of 52.7% and 51.7%, respectively.”

    Humanshealthyheart

    What is a normal left ventricular ejection fraction in healthy adults? A meta-analysis of population-based echocardiographic studies

    Journal of cardiovascular imaging

  2. female sex is associated with left ventricular ejection fraction in humans (centenarians) (58.4 ± 9.8 vs 51.6 ± 14.6%).

    “females vs males, 58.4 ± 9.8 vs 51.6 ± 14.6%, p = 0.01”

    Humanscentenariansheartn = 100

    Echocardiographic Features of Longevity: A Cross-Sectional Study of Centenarians

    Cureus

Frailty

downin humans2

2 studies
  1. Left ventricular ejection fraction is linked with a lower risk of frailty in humans (hospitalized patients with chronic heart failure).

    “albumin and LVEF were protective factors.”

    Humanshospitalized patients with chronic heart failuren = 256

    Status and influencing factors of frailty in hospitalized patients with chronic heart failure: A cross-sectional study

    Journal of clinical nursing

  2. Left ventricular ejection fraction is associated with frailty in chronic heart failure.

    “Conversely, higher albumin, hemoglobin, and left ventricular ejection fraction (LVEF) levels were negatively associated with frailty.”

    Reviewin chronic heart failure

    Prevalence and Associated Factors of Frailty in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis

    Reviews in cardiovascular medicine

Activities of Daily Living score

upin humans1

1 study
  1. Left ventricular ejection fraction is associated with activities of Daily Living score in humans (0.69-point higher ADL score per 10% higher LVEF (95% CI 0.16–1.22; q = 0.032)).

    “each 10% higher LVEF was associated with a 0.69-point higher ADL score (95% CI, 0.16–1.22; q = 0.032)”

    HumansHospitalized patients with atrial fibrillation; adjusted for age and previous ischemic stroke51.8% womensn = 83

    Lower Left Ventricular Ejection Fraction Is Associated with Reduced Functional Independence in Patients with Atrial Fibrillation: An Exploratory Cross-Sectional Study

    Biomedicines

Non-response to SGLT2 inhibitors

upin humans1OR 1.89

1 study
  1. Left ventricular ejection fraction predicts non-response to SGLT2 inhibitors in humans (heart failure with reduced ejection fraction; baseline LVEF ≤25%) (OR 1.89, 95% CI 1.53-2.34 for baseline LVEF ≤25%).

    “baseline LVEF ≤25% (OR 1.89, 95% CI 1.53-2.34)”

    Humansheart failure with reduced ejection fraction; baseline LVEF ≤25%6-12 monthsn = 4,723

    Real-World Predictors of Non-Response to SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Retrospective Cohort Study from a Tertiary Care Center in Central India of 4723 Patients

    AHA Scientific Sessions 2026 abstract

Heart rate variability

upin humans1OR 1.42

1 study
  1. Heart rate variability predicts left ventricular ejection fraction in humans (Heart failure; SDNN >35 ms) (OR 1.42 for LVEF improvement, 95% CI 1.28 to 1.57).

    “Higher HRV (SDNN >35 ms) predicted LVEF improvement (OR 1.42, 95% CI 1.28 to 1.57; p<0.001).”

    HumansHeart failure; SDNN >35 msheartMedian 8.2 months54% malesn = 8,000

    Association of Wearable-Derived Physical Activity and Weight Trajectories with Reverse Remodeling on Serial Echocardiography in 8,000 Heart Failure Patients: A Retrospective Multi-Center Cohort Study

    AHA Scientific Sessions 2026 abstract

More on Heart rate variability

Major adverse cardiovascular events

downin humans1OR 0.96

1 study
  1. Left ventricular ejection fraction is associated with major adverse cardiovascular events in humans (Atrial fibrillation undergoing index pulmonary vein isolation) (OR 0.96, 95% CI 0.94–0.98; p<0.001).

    “LVEF before index PVI (Odds Ratio (95%CI) 0.96 (0.94; 0.98), p<0.001) and regular sports (0.49 (0.29; 0.81), p<0.001) were strongly associated with MACE”

    HumansAtrial fibrillation undergoing index pulmonary vein isolationMedian follow-up of 30 monthsBothsn = 2,273

    Major adverse cardiovascular events and their predictors in patients with atrial fibrillation undergoing pulmonary vein isolation: the Swiss-AF-PVI study

    ESC Congress 2026 abstract

Cardiomyopathy

downin humans1

1 study
  1. Cardiomyopathy is associated with left ventricular ejection fraction in humans (Patients with acute heart failure; compared with other etiologic groups) (LVEF 34%).

    “patients with cardiomyopathy had the lowest LVEF (34%) compared to other groups (p<0.001).”

    HumansPatients with acute heart failure; compared with other etiologic groupsheart

    THe Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II): Aetiology, 30- days and 6 months outcome

    ESC Congress 2026 abstract

More on Cardiomyopathy

PEP/ET ratio

downin humans1

1 study
  1. PEP/ET ratio is associated with left ventricular ejection fraction in humans (At least one cardiovascular risk factor; PEP/ET ≥0.425 versus <0.425) (57.0 ± 12.1 vs. 66.3 ± 9.6%; p<0.001).

    “LVEF was significantly lower in the high-PEP/ET group than in the low-PEP/ET group (57.0 ± 12.1 vs. 66.3 ± 9.6%, p<0.001).”

    HumansAt least one cardiovascular risk factor; PEP/ET ≥0.425 versus <0.425heartn = 415

    A heart timing marker is linked to higher heart failure risk

    ESC Congress 2026 abstract

More on PEP/ET ratio

Pulse wave velocity

downin humans1

1 study
  1. Pulse wave velocity is associated with left ventricular ejection fraction in lymphoma patients receiving anthracycline-based chemotherapy (-2.7%, 95% CI -4.65 to -0.81).

    “A ≥1 SD increase in PWV was associated with a mean LVEF decline of 2.7% (95% CI -4.65 to -0.81, p=0.006).”

    Human trialin lymphoma patients receiving anthracycline-based chemotherapyn = 152

    Atorvastatin and Pulse Wave Velocity in Anthracycline-based Chemotherapy

    AHA Scientific Sessions 2025 abstract

More on Pulse wave velocity

Cardiac resynchronization therapy

upin humans1

1 study
  1. Cardiac resynchronization therapy is associated with left ventricular ejection fraction in humans (heart failure) (35±8 vs. 28±5%).

    “CRT was associated with the improvement of LVEF (35±8 vs. 28±5%, p<0.001)”

    Human trialheart failureheart6 months80% mensn = 54

    Cardiac resynchronization therapy improves functional status and cognition

    International journal of cardiology

More on Cardiac resynchronization therapy

All 44

Funding

1 grant since 2020

Japan Society for the Promotion of Science¥3.8M

Latest

Dec 2025: 17Jan 2026: 60Feb 2026: 57Mar 2026: 59Apr 2026: 10May 2026: 13Jun 2026: 14Jul 2026: 18Aug 2026: 25Sep 2026: 32Oct 2026: 211Nov 2026: 116632 papers in 12 months

See all 1,104 papers on left ventricular ejection fraction